Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5.17M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
10.5M
-
Shares change
-
+9.12M
-
Total reported value, excl. options
-
$104M
-
Value change
-
+$90.4M
-
Number of buys
-
32
-
Price
-
$9.91
Significant Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q4 2021
36 filings reported holding CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.5M shares
.
Largest 10 shareholders include Beryl Capital Management LLC (1.23M shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (1.04M shares), CANTOR FITZGERALD, L. P. (750K shares), CITADEL ADVISORS LLC (750K shares), Saba Capital Management, L.P. (640K shares), MARSHALL WACE, LLP (627K shares), Polar Asset Management Partners Inc. (600K shares), D. E. Shaw & Co., Inc. (476K shares), Weiss Asset Management LP (467K shares), and Atalaya Capital Management LP (450K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.